Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level.

Michael Braun, Antonia Kriegmair,Nina Szeterlak, Anne Andrulat, Simone Schrodi, Monika Kriner,Claus Hanusch,Moritz Hamann,Oliver Stoetzer,Martin Pölcher

Breast care (Basel, Switzerland)（2022）

引用 0|浏览0

暂无评分

摘要

The results of the study confirm the observations from randomized studies on the use of the ODX® in a real-world population in terms of risk distribution and patient outcome. Adjuvant chemotherapy could be safely omitted in patients with HR*/HER2- breast cancer with 0-3 positive lymph nodes and RS <25.

查看译文

关键词

21-gene recurrence score,Luminal breast cancer,Outcome

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要